Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0662-0419 in Type 2 Diabetes
NCT07415954Phase 2Recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2026
- Primary completion
- Sep 2027
- Modality
- Peptides, Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of NNC0662-0419 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Glycated haemoglobin at 40 weeks. Started Apr 2026; status: recruiting.
02
Drugs
NNC0662-0419
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07415954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07415954.